We set up an interview with David Spetzler, the CSO of Caris Life Sciences, to hear about some promising new liquid biopsy tests they are developing. And we do that in today’s show. But first, the interview takes a turn toward the regulation of molecular tests. Spetzler says that Caris is already doing as many quality certifications as possible short of FDA oversight.
Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler
www.mendelspod.com
Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.Listen on
Substack App
RSS Feed
Appears in episode
Theral Timpson
Recent Episodes
Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler